Skip to main content
Fig. 3 | Journal of Biological Research-Thessaloniki

Fig. 3

From: Combined study on clastogenic, aneugenic and apoptotic properties of doxorubicin in human cells in vitro

Fig. 3

% DNA in tail in HL-60 comets after treatment with doxorubicin and incubation of nucleoids with Fpg or hOGG1 endonuclease. Data represent values generated by Fpg (a1) and hOGG1 (a2) incubation, that were calculated by subtracting the value of DNA damage caused in the HL-60 cells that were not treated with the respective enzyme from the DNA damage caused in cells incubated with the enzymes. Subtracted values are pointed out in light grey area marked ‘‘Fpg sites’’ and “hOGG1 sites”. b HL-60 comets, no doxorubicin treatment/no endonuclease incubation (b1); no doxorubicin treatment/Fpg endonuclease incubation (b2); no doxorubicin treatment/hOGG1 endonuclease incubation (b3); doxorubicin treatment at 0.5 μg ml−1/no endonuclease incubation (b4); doxorubicin treatment at 0.5 μg ml−1/Fpg endonuclease incubation (b5); doxorubicin treatment at 0.5 μg ml−1/hOGG1 endonuclease incubation (b6); doxorubicin treatment at 2.0 μg ml−1/no endonuclease incubation (b7); doxorubicin treatment at 2.0 μg ml−1/Fpg endonuclease incubation (b8) and doxorubicin treatment at 2.0 μg ml−1 /hOGG1 endonuclease incubation (b9). DNA was stained with ethidium bromide. * p ≤ 0.05 in comparison with untreated cells (one-way ANOVA). Bars represent standard error

Back to article page